Mepro Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Mepro Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 11 Products, $17.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mepro Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 11 Products, $17.5M Trade | TransData Nexus

Mepro Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $17.5M Total Trade · DGFT Verified

Mepro Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $17.5M across 11 products in 6 therapeutic categories. Based on 774 verified export shipments from Indian Customs (DGFT) records, Mepro Pharmaceuticals Private Limited is the #1 Indian exporter in 1 product including Albendazole. Top exports include Albendazole ($4.9M), Hydrocortisone ($2.5M), Clotrimazole ($2.2M).

Mepro Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Mepro Pharmaceuticals Private Limited pharmaceutical export portfolio — 11 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Mepro Pharmaceuticals Private Limited? — Company Overview & Market Position

Mepro Pharmaceuticals Private Limited, established on August 31, 1982, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24231GJ1982PTC005451. As of March 2026, Mepro's authorized share capital stands at ₹54 million, with a paid-up capital of ₹53.46 million. The company specializes in the manufacture of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories. Mepro's product portfolio encompasses 11 products spanning six therapeutic areas, with a significant focus on Antimalarial & Antiparasitic, Antifungals, and Cardiovascular segments. The company's total export value amounts to $17.5 million USD, distributed across 774 shipments. Notably, Mepro holds a dominant position in the Albendazole market, commanding a 6.8% share.

What Does Mepro Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Albendazole$4.9M 2

Product Portfolio — Top 11 by Export Value

Mepro Pharmaceuticals Private Limited exports 11 pharmaceutical products across 6 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Albendazole	Antimalarial & Antiparasitic	$4.9M	98	6.8%	1
2	Hydrocortisone	Corticosteroids	$2.5M	150	3.7%	6
3	Clotrimazole	Antifungals	$2.2M	121	2.4%	8
4	Simvastatin	Cardiovascular	$2.0M	40	1.6%	12
5	Zinc	Vitamins & Supplements	$1.6M	73	2.0%	9
6	Miconazole	Antifungals	$1.5M	115	7.8%	2
7	Doxycycline	Antibiotics	$1.1M	65	0.9%	14
8	Irbesartan	Cardiovascular	$1.0M	71	1.0%	14
9	Pyrimethamine	Antimalarial & Antiparasitic	$262.4K	11	0.6%	11
10	Terbinafine	Antifungals	$225.0K	17	0.8%	13
11	Pyrantel	Antimalarial & Antiparasitic	$166.6K	13	5.1%	5

Mepro Pharmaceuticals Private Limited exports 11 pharmaceutical products across 6 therapeutic categories with a total export value of $17.5M. The company is the #1 Indian exporter in 1 product: Albendazole. The top category is Antimalarial & Antiparasitic (30.5% of portfolio), followed by Antifungals (22.9%), indicating a concentrated portfolio with the top 5 products accounting for 75.5% of total export value.

Mepro Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Mepro Pharmaceuticals operates four state-of-the-art manufacturing facilities located in different cities across India. These facilities collectively cover a constructed area of 300,000 square feet, enabling the production of a diverse range of pharmaceutical products. The manufacturing plants are equipped with advanced technology and precision-driven processes to ensure adherence to stringent quality standards. The company's commitment to quality is evident from its approvals by regulatory bodies such as the UK's MHRA and other PIC/S nations.

3Key Leadership

Mepro Pharmaceuticals is led by a team of experienced directors:

Vijay Chhabildas Shah
Suresh Chhabildas Shah
Rajesh Sumanlal Shah
Bharatkumar Chabildas Shah
Prakash Navinchandra Shah

These directors have been instrumental in steering the company towards sustained growth and innovation in the pharmaceutical sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Mepro Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Mepro Pharmaceuticals has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has secured approvals from the UK's MHRA and other PIC/S nations, reflecting its compliance with international quality standards. Mepro has also been a partner of choice for several United Nations organizations, supplying healthcare products to regions such as the West Bank, Gaza, Lebanon, Jordan, and Syria.

2Emerging Markets

Mepro Pharmaceuticals has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to addressing neglected tropical diseases is evident through its collaboration with global non-profit organizations to manufacture and supply treatments for conditions like Soil Transmitted Helminths (STH). Through these partnerships, Mepro reaches approximately 42 million children annually, contributing to the global effort in eradicating such diseases.

3Geographic Strategy

Mepro Pharmaceuticals demonstrates a diversified geographic strategy by exporting to over 40 countries, including both regulated and emerging markets. This broad market presence mitigates concentration risk and positions the company to leverage growth opportunities across different regions. The strategic direction focuses on expanding into new markets while strengthening its position in existing ones, ensuring a balanced and sustainable growth trajectory.

Mepro Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Mepro Pharmaceuticals has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), indicating its commitment to meeting U.S. regulatory standards. The company has filed Abbreviated New Drug Applications (ANDAs) for various products, seeking approval for marketing in the U.S. market. Mepro's facilities have undergone FDA inspections, reflecting the company's adherence to Good Manufacturing Practices (GMP). The company has also filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its products.

2WHO & EU GMP

Mepro Pharmaceuticals has achieved World Health Organization (WHO) prequalification for certain products, facilitating access to international markets and enhancing the company's credibility in the global pharmaceutical industry. The company's manufacturing facilities hold European Union Good Manufacturing Practice (EU GMP) certificates, demonstrating compliance with EU standards for pharmaceutical manufacturing. Additionally, Mepro's facilities are recognized by the European Directorate for the Quality of Medicines & HealthCare (EDQM), further validating the quality of its manufacturing processes.

CDSCO & Indian Regulatory

Mepro Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Mepro Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific market share data is not publicly disclosed, Mepro's focus on niche and technically complex pharmaceutical products positions it uniquely in the market. The company's strategic partnerships, including collaborations with United Nations organizations, further enhance its competitive edge. Mepro's commitment to quality and regulatory compliance distinguishes it from competitors, enabling the company to secure and maintain a strong market presence.

2Key Differentiators

Mepro Pharmaceuticals' key differentiators include its extensive experience of over three decades in the pharmaceutical industry, a diverse product portfolio spanning multiple therapeutic categories, and a strong emphasis on quality and regulatory compliance. The company's state-of-the-art manufacturing facilities and dedicated research and development capabilities enable it to deliver innovative and high-quality pharmaceutical products. Mepro's strategic focus on addressing neglected tropical diseases and its partnerships with global organizations underscore its commitment to global health initiatives.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Mepro Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Mepro Pharmaceuticals has a commendable track record in pharmaceutical manufacturing, characterized by consistent export volumes and adherence to international quality standards. The company's reliability is evidenced by its partnerships with over 50 clients across more than 40 countries, and its ability to meet the stringent requirements of regulatory bodies such as the UK's MHRA and other PIC/S nations. Mepro's commitment to quality and compliance positions it as a dependable supplier in the global pharmaceutical market.

2Certifications to Verify

Importers should verify the following certifications when considering Mepro Pharmaceuticals as a supplier:

FDA Facility Registration: Confirm the registration status of Mepro's manufacturing facilities with the U.S. Food and Drug Administration.

WHO Prequalification: Verify the WHO prequalification status of Mepro's products to ensure compliance with international quality standards.

Frequently Asked Questions — Mepro Pharmaceuticals Private Limited

How many pharmaceutical products does Mepro Pharmaceuticals Private Limited export from India?

Mepro Pharmaceuticals Private Limited exports 11 pharmaceutical products across 6 therapeutic categories. The top exports are Albendazole ($4.9M), Hydrocortisone ($2.5M), Clotrimazole ($2.2M), Simvastatin ($2.0M), Zinc ($1.6M). Total export value is $17.5M.

What is Mepro Pharmaceuticals Private Limited's total pharmaceutical export value?

Mepro Pharmaceuticals Private Limited's total pharmaceutical export value is $17.5M, based on 774 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Mepro Pharmaceuticals Private Limited the #1 Indian exporter?

Mepro Pharmaceuticals Private Limited is the #1 Indian exporter in 1 products: Albendazole (6.8% market share).

What therapeutic categories does Mepro Pharmaceuticals Private Limited cover?

Mepro Pharmaceuticals Private Limited exports across 6 therapeutic categories. The largest are Antimalarial & Antiparasitic (30.5%, 3 products), Antifungals (22.9%, 3 products), Cardiovascular (17.4%, 2 products).

Get Full Mepro Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.